Key information

Use of proceeds

The net proceeds from the Placing will be used to facilitate the development of the Company's Chimeric Antigen Receptor T-cells ("HEMO-CAR-T") for the treatment of acute myeloid leukaemia ("AML").

Company announcement

https://www.londonstockexchange.com/news-article/HEMO/placing-to-raise-us-4-2-million/16354098

Legal information

• Legal Documents
• Risk Warning

Important notices

This website contains links to other websites and resources provided by third parties. These links are provided for your information only and we accept no responsibility for them or for any loss or damage that may arise from your use of them.

Investing in financial products involves taking risk. The value of investments can go up as well as down and you may receive back less than your original investment. CMC Markets UK plc trading as CMC CapX (“CMC”) does not provide investment advice of any kind and individual investors should make their own decisions or seek independent advice regarding the merits of entering into, and the suitability of, any investment. Nothing on this website and no communication from CMC should be construed as an investment recommendation. Only professional clients and eligible counterparties are eligible to participate in any offering in connection with CMC's services. There are inherent risks associated with investing in such offerings and such investments should only be made as part of a diversified portfolio. Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful.

Please read our Risk Warning before making any investment decisions.